For instance, mAbs inhibiting CD44 binding to hyaluronan have stood up as candidate immunotherapeutic agents for treatment of B-CLL [129, 130], much because of the tight signal transduction linkage of CD44 with ZAP70 (a recognized prognostic CLL-B marker). This evidence concerns the gene ZAP70 and B-cell chronic lymphocytic leukemia.